

28 February 2024
EMA/567941/2023
Stakeholders and Communication Division

Agenda – Joint Patients' and Consumers' (PCWP) and Healthcare Professionals' (HCPWP) working parties meeting

27 and 28 February 2024 – meeting room: 2A / Webex

Co-Chairs: Juan Garcia-Burgos (EMA), Marko Korenjak (PCWP), Rosa Giuliani (HCPWP)

Day 1: 27 February, 13:30–18:30 CET

Time	Topics	Speakers
13:15	<i>Joining and technical checks</i>	
13:30 (10')	Welcome and introduction to joint meeting	Juan Garcia Burgos (EMA)
1. Working party operations		
13:40 (10')	1.1. Working party work plan – mid-mandate review	Ivana Silva (EMA)
13:50 (10')	1.2. Stakeholder Engagement report - overview	Maria Filancia (EMA)
14:00 (10')	1.3. HMH (human medicines highlights) newsletter – new format	Kaisa Immonen (EMA)
14:10 (15')	Q&A	All
2. Third party interventions		
14:25 (10')	2.1. Third party contributions during ongoing assessments	Fabrizio Boccacci (EMA)
14:35 (25')	Q&A	All
15:00 (15')	<i>Coffee break</i>	
3. What is happening in cancer		
15:15 (15')	3.1. Cancer Medicines as pathfinder	Francesco Pignatti (EMA)
15:30 (15')	3.2. Conversations on Cancer	Caroline Voltz (EMA)
15:45 (35')	Q&A	All

Time	Topics	Speakers
4. Update on progress with Patient Experience Data		
16:20 (15')	4.1. Patient experience data reflection paper	Rosa Gonzalez-Quevedo (EMA)
16:35 (10')	4.2. Action plan (therapeutic area priorities), consultation and next steps – survey	Rosa Gonzalez-Quevedo (EMA),
16:45 (30')	Q&A	All
5. Update on training resources		
17:15 (15')	5.1. Update on the Network Training Centre	Esther Martinez (EMA)
17:30 (10')	Q&A	All
6. Policy on competing interests		
17:40 (15')	6.1. EMA's policy on competing interests	Zahra Hanaizi (EMA), Hilde Boone (EMA)
17:55 (35')	Q&A	All
18:30	<i>End of day 1</i>	

Day 2: 28 February, 09:00–16:00 CET

Time	Topics	Speakers
08:45	Joining and technical checks	
09:00 (5')	Welcome and introduction to joint meeting	Juan Garcia Burgos (EMA)
7. Pharmacovigilance		
09:05 (20')	7.1. Preparation of amendments to Commission Implementing Regulation 520/2012 on the performance of pharmacovigilance activities	Izabela Taborska (EC, DG Santé)
09:25 (20')	Q&A	All
09:45 (25')	7.2. Risk minimisation for patient safety – update on policies and practices	Priya Bahri (EMA)
10:10 (20')	Q&A	All
10:30 (15')	Coffee break	
8. Feedback from Patient and HCP representatives in EMA groups		
10:45 (20')	8.1. European Network of Paediatric Research at EMA (Enpr-EMA)	Gunter Egger (EMA), Jose Drabwell (IPOPI)
11:05 (10')	Q&A	

Time	Topics	Speakers
11:15 (10') (10')	8.2. Review of the package leaflet template <ul style="list-style-type: none">Update on the QRD subgroupFeedback from patient, consumer and HCP members of the subgroup	Monica Buch (EMA) Courtney Davis (HAI)
11:35 (25')	Q&A	All
12:00 (60')	Lunch break	
9. Ongoing EMA activities		
13:00 (20')	9.1. COVID-19: Outcome of Long COVID workshop – EMA and patient perspectives	Stephanie Buchholz (EMA), Chantal Britt (Long COVID Europe)
13:20 (30')	Q&A	All
13:50 (15')	9.2. ACT EU: summary of recent workshops and establishment of the Multistakeholder Platform (MSP) Advisory Groups	Ana Zanoletty (EMA), Maria Filancia (EMA)
14:05 (15')	Q&A	All
14:20 (15')	9.3. Data discoverability: HMA-EMA Catalogues of Real-World Data sources and studies	Ana Cochino (EMA)
14:35 (15')	Q&A	All
14:50 (20')	Coffee break	
10. Shortages		
15:10 (10')	10.1. Next phase to complete and extend the Union list of critical medicines	Joao Francisco Ferreira (EMA)
15:20 (10')	Q&A	All
15:30 (10')	10.2. Update on shortage of glucagon-like peptide-1 receptor agonists (GLP-1 RAs)	Klaus Kruttwig (EMA), Romana Micovcakova (EMA)
15:40 (5')	Q&A	All
15:45 (15')	AOB	Juan Garcia Burgos (EMA)
16:00	End of meeting	